Structure Therapeutics Inc.
HealthcareNASDAQ:GPCR · NASDAQ Global Market
-$0.37 today
Vol 0.54M · Avg 0.91M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-9.3%
avg 22.3%
ROIC
-18.9%
avg -33.7%
ROA
-8.9%
avg -28.4%
Analysis
ROA is currently the strongest return metric at -8.9% versus its period average of -28.4%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Raymond C. Stevens | Chief Executive Officer & Director | $1.19M | — | 62 | $1.40M | 2.43% |
Jun S. Yoon | Co- Founder, Chief Financial Officer & Secretary | $850,134.00 | — | 48 | $1.40M | 2.43% |
Xichen Lin | Chief Scientific Officer & GM of Structure Shanghai | $762,416.00 | — | 52 | $228,960.00 | 0.40% |
Blai Coll | Chief Medical Officer | $759,964.00 | — | 52 | $280,878.00 | 0.49% |
Yingli Ma | Chief Technology Officer | $642,360.00 | — | 52 | $139,917.00 | 0.24% |
Matthew Lang | COO & General Counsel | — | — | 50 | $223,776.00 | 0.39% |
Hui Lei | Senior Vice President of Chemistry | — | — | — | — | — |
Xinglong Jiang | Senior Vice President of Preclinical Development | — | — | — | — | — |
Fang Zhang | Executive Vice President & Head of Biology | — | — | — | — | — |
Sam Lim | Senior Vice President of Cardiopulmonary Clinical Development | — | — | — | — | — |
Tony Peng | Senior Vice President of Legal | — | — | — | — | — |
Lani Ibarra | Senior Vice President of Clinical Development Operations | — | — | — | — | — |
Bob Gatmaitan | Senior Vice President of People | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
21
$0.00
Net Sentiment
+$0.00
Net buying
Most Active
FMR LLC
21 transactions
1–10 of 21
Analysis
Insiders reported 0 buys worth $0.00 and 21 sells worth $0.00 over the last 12 months. That adds up to net buying of $0.00. FMR LLC was the most active insider with 21 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A6 analysts |
| Revenue | N/A | N/A | N/A | N/A5 analysts |
| Net Income | N/A | N/A | N/A | N/A5 analysts |
| EBIT | N/A | N/A | N/A | N/A5 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Liquidia Corporation
NASDAQ:LQDA
$6.33B
Edgewise Therapeutics, Inc.
NASDAQ:EWTX
$3.75B
Celldex Therapeutics, Inc.
NASDAQ:CLDX
$2.08B
Ocular Therapeutix, Inc.
NASDAQ:OCUL
$1.96B
Galapagos N.V.
GLPG
$1.84B
Mesoblast Limited
NASDAQ:MESO
$1.79B
uniQure N.V.
NASDAQ:QURE
$1.74B
Nuvation Bio Inc.
NYSE:NUVB
$1.71B
AbCellera Biologics Inc.
NASDAQ:ABCL
$1.60B
Viridian Therapeutics, Inc.
NASDAQ:VRDN
$1.47B
Who manages GPCR?
Structure Therapeutics Inc. (GPCR) lists 13 active executives. The top listed executive is Matthew Lang, COO & General Counsel.
Are GPCR insiders buying or selling?
Recent insider activity shows net buying of $74.70M.
Explore More
Continue the stock analysis
Jump to another research area for this company.